Eli Lilly and Co (NYSE:LLY) shares hit a new 52-week low during trading on Thursday . The company traded as low as $75.50 and last traded at $76.18, with a volume of 4498367 shares trading hands. The stock had previously closed at $76.72.

A number of research analysts have commented on LLY shares. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the company from $85.52 to $115.00 in a research report on Friday, January 5th. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 12th. Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Morgan Stanley increased their price target on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 21st. Finally, Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and an average price target of $92.02.

The firm has a market capitalization of $81,712.27, a P/E ratio of -381.13, a price-to-earnings-growth ratio of 1.36 and a beta of 0.23. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.95 earnings per share. equities research analysts predict that Eli Lilly and Co will post 4.87 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is -1,039.95%.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now directly owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 259,610 shares of company stock valued at $22,727,406. Insiders own 0.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Pathstone Family Office LLC lifted its stake in Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock worth $4,774,000 after acquiring an additional 29 shares during the period. Vantage Financial Partners Ltd. Inc. purchased a new stake in Eli Lilly and in the second quarter worth $494,000. Gradient Investments LLC purchased a new stake in Eli Lilly and in the fourth quarter worth $103,000. Acrospire Investment Management LLC lifted its stake in Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the period. Finally, MPS Loria Financial Planners LLC purchased a new stake in Eli Lilly and in the second quarter worth $128,000. 76.45% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/eli-lilly-and-lly-sets-new-12-month-low-at-75-50/1857957.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.